Consult healthcare providers before using any peptide protocol.
There were no significant differences in the extent of HbA1c decrease either between no/low CKD risk and CKD patients, or among CKD patients when these were categorized according to severity ( Table 3 )
Wegovy uses the higher 2.4 mg dose approved specifically for chronic weight management
On the heels of the exciting findings for the six-week study, longer interventions are underway
During treatment, monitoring is required regarding the potential occurrence of acute pancreatitis, gallbladder disease, suicidal ideation, medullary thyroid carcinoma, acute kidney injury, and worsening of diabetic retinopathy (15, 17, 18)
No matter the approach, its vital to track how it affects drug use, PBM/vendor deals, and overall medical costs